Advertisement
UK markets close in 7 hours 30 minutes
  • FTSE 100

    8,352.73
    -1.32 (-0.02%)
     
  • FTSE 250

    20,483.84
    -8.15 (-0.04%)
     
  • AIM

    781.34
    +1.51 (+0.19%)
     
  • GBP/EUR

    1.1618
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.2477
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    49,035.24
    -798.44 (-1.60%)
     
  • CMC Crypto 200

    1,308.58
    +8.48 (+0.65%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CRUDE OIL

    79.53
    +0.54 (+0.68%)
     
  • GOLD FUTURES

    2,315.60
    -6.70 (-0.29%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • HANG SENG

    18,522.10
    +208.24 (+1.14%)
     
  • DAX

    18,545.68
    +47.30 (+0.26%)
     
  • CAC 40

    8,126.31
    -5.10 (-0.06%)
     

Company News for Dec 4, 2019

  • UnitedHealth Group Inc.’s UNH shares fell 1% after the company declared that its full year 2020 adjusted earnings per share will be in the range of $16.25-$16.55. Its mid-point of $16.40 lagged the current Zacks Consensus Estimate of $16.44.

  • PepsiCo Inc. PEP dropped 0.3% after the company decided to acquire BFY Brands Inc. for an undisclosed sum.

  • Shares of Cleveland-Cliffs Inc. CLF plunged 10.7% following its decision to acquire AK Steel Holding Corp. AKS for a consideration of $1.1 billion in an all-stock deal.

  • Audentes Therapeutics Inc. BOLD jumped 106% following news that Japan’s Astellas Pharma Inc. will acquire the company for a consideration of $3 billion in cash.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
 
UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report
 
Cleveland-Cliffs Inc. (CLF) : Free Stock Analysis Report
 
AK Steel Holding Corporation (AKS) : Free Stock Analysis Report
 
Audentes Therapeutics, Inc. (BOLD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research